➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
McKesson
Medtronic
Merck
Boehringer Ingelheim

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PITAVASTATIN CALCIUM

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for pitavastatin calcium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02056847 to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia Unknown status Ajou University School of Medicine Phase 4 2014-01-01 Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
NCT02056847 to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia Unknown status Asan Medical Center Phase 4 2014-01-01 Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
NCT02056847 to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia Unknown status Chonbuk National University Hospital Phase 4 2014-01-01 Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
NCT02056847 to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia Unknown status Chonnam National University Hospital Phase 4 2014-01-01 Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
NCT02056847 to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia Unknown status Chungnam National University Hospital Phase 4 2014-01-01 Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
NCT02056847 to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia Unknown status Dong-A University Hospital Phase 4 2014-01-01 Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for pitavastatin calcium

Condition Name

Condition Name for pitavastatin calcium
Intervention Trials
Prediabetic State 1
Hypertension 1
HbA1c Level Associated With Lipid Compositions 1
Dyslipidemias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for pitavastatin calcium
Intervention Trials
Prediabetic State 1
Hypertension 1
Dyslipidemias 1
Hyperlipidemias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for pitavastatin calcium

Trials by Country

Trials by Country for pitavastatin calcium
Location Trials
China 7
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for pitavastatin calcium

Clinical Trial Phase

Clinical Trial Phase for pitavastatin calcium
Clinical Trial Phase Trials
Phase 4 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for pitavastatin calcium
Clinical Trial Phase Trials
Recruiting 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for pitavastatin calcium

Sponsor Name

Sponsor Name for pitavastatin calcium
Sponsor Trials
Dong-A University Hospital 1
Samsung Medical Center 1
The Catholic University of Korea Uijeongbu St.Marys Hostpial 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for pitavastatin calcium
Sponsor Trials
Other 23
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Medtronic
McKinsey
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.